Study of ZE94-0605 in Patients With Advanced Solid Tumors, With Dose Expansion Cohorts.

Phase 1 Not yet recruiting 60 enrolled Eilean Therapeutics

Non-randomizedSequentialOpen-labelTreatment

Summary

Phase 1 Study of ZE94-0605 in solid tumors who have exhausted all treatment options and then with expansion into two dose cohorts in select solid tumor patients.

Timeline

Start: 2026-04
Primary completion: 2028-01
Completion: 2028-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	ZE94-0605	Unknown	—	Oral

Study of ZE94-0605 in Patients With Advanced Solid Tumors, With Dose Expansion Cohorts.

Summary

Timeline

Drugs

Indications